Form 4: LivaNova PLC Executive Granted Stock Awards

Franco Poletti, President of Cardiopulmonary at LivaNova PLC, received grants of restricted stock units, performance stock units, and stock appreciation rights on September 15, 2024.

Summary

• Franco Poletti, President of Cardiopulmonary at LivaNova PLC, filed a Form 4 on September 17, 2024, reporting changes in beneficial ownership.
• On September 15, 2024, Poletti was granted 2,575 restricted stock units (RSUs) that vest in equal annual installments over four years, starting September 15, 2025.
• He also received three grants of 1,287, 1,287 and 2,575 performance stock units (PSUs) each, which vest or lapse on March 30, 2027, based on the company's free cash flow (FCF), return on invested capital (ROIC), and total shareholder return (TSR) performance over the period 2024-2026.
• Additionally, Poletti was granted 5,885 stock appreciation rights (SARs) that vest in equal annual installments over four years, starting September 15, 2025, with an exercise price of $48.53 and expiring on September 15, 2034.
• All awards are subject to the terms of the company's 2022 Incentive Award Plan and the respective award agreements.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a positive outlook for the company's performance and alignment of management interests with shareholders.

Positives

• The grants of RSUs, PSUs, and SARs align executive compensation with the company's long-term performance and shareholder value.
• The vesting schedules for the RSUs and SARs encourage continued service and commitment from the executive.
• The performance-based vesting criteria for the PSUs incentivize the achievement of specific financial goals, such as FCF, ROIC, and TSR.

Risks

• The value of the stock awards is subject to the company's stock price performance, which can be influenced by various market and company-specific factors.
• The vesting of the PSUs is contingent upon the company achieving certain financial targets, which may not be met.
• Forfeiture of the awards is possible prior to vesting, according to the terms of the Plan and the award agreement.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules and performance criteria for the stock awards.

Industry Context

Stock awards are a common practice in publicly traded companies to incentivize executives and align their interests with those of shareholders. The specific terms of the awards, such as vesting schedules and performance criteria, vary depending on the company's compensation philosophy and industry practices.

Comparison to Industry Standards

• Stock awards are a common component of executive compensation packages in publicly traded companies, particularly in the healthcare and medical device industries.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize a mix of restricted stock units, performance-based equity, and stock options to incentivize their executives.
• The vesting schedules and performance metrics used by LivaNova are generally in line with industry standards, with a focus on long-term value creation and shareholder returns.

Stakeholder Impact

• Shareholders: The stock awards aim to align executive interests with shareholder value creation.
• Employees: The awards may motivate the executive to drive company performance, potentially benefiting all employees.

Key Dates